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ABSTRACT
Objectives: We compared the perioperative morbidity of
laparoscopic hysterectomy for gynecologic oncologic
(group A) and benign gynecologic (group B) indications
at a single institution.
Methods: This is a retrospective analysis of 159 consec-
utive cases of laparoscopic hysterectomy at a tertiary care
university hospital. It includes 74 women with gyneco-
logic cancers and 85 women with benign gynecologic
conditions.
Results: Patients in group A were significantly older and
had higher body mass index (P0.001). The differences in
mean blood loss (A, 201.1 mL; B, 183.6 mL, P0.504),
conversion to laparotomy (2 for each group), and wound
infection (none) were not significant in the 2 groups. The
mean operating time (253.2 and 188.2 minutes, P0.001)
and the mean length of hospital stay (3.5 days and 2.5
days, P0.001) were significantly longer in group A.
Transfusion was required for 2 patients in group A and 4
in group B. One intraoperative injury to the bladder oc-
curred in group A.
Conclusions: In spite of older age and longer operative
time in cancer patients, there was no difference in peri-
operative complications associated with laparoscopic hys-
terectomy for gynecologic malignancies compared with
benign gynecologic conditions.
Key Words: Laparoscopic hysterectomy, Perioperative
morbidity, Gynecologic cancers.
INTRODUCTION
Hysterectomy is a common operation, with up to 600,000
procedures undertaken annually in the United States. The
advent of laparoscopic approaches to hysterectomy offers
the prospect of improved outcomes and gains in cost
effectiveness through reduced severity of convalescence
and shorter length of hospital stay. For women who re-
quire hysterectomy, the appropriate route of surgery is
determined by anatomic considerations, the type of
pathologic condition expected, patient preference, and
physician experience and training.
Prospective randomized trials have demonstrated that to-
tal laparoscopic hysterectomy (TLH) and laparoscopically
assisted vaginal hysterectomy (LAVH) for benign indica-
tions are associated with faster recovery, less postopera-
tive pain, less blood loss, fewer transfusions, and similar
complication rates compared with abdominal hysterecto-
my.1 However, due to fewer studies and less experience,
the outcomes of laparoscopic hysterectomy for oncologic
indications are less clear. We hypothesize that there is no
difference in surgical outcome of patients who undergo
laparoscopic hysterectomy for oncologic and benign gy-
necologic conditions. We compared the perioperative
morbidity of 159 consecutive laparoscopic hysterectomies
for gynecologic oncologic and benign gynecologic indi-
cations at our institution.
METHODS
From July 2000 to June 2004, 159 patients underwent
laparoscopic hysterectomy for gynecologic oncologic
(group A) and benign gynecologic (group B) conditions at
the Division of Gynecologic Oncology, Mount Sinai Med-
ical Center (Table 1). The indications for hysterectomy in
74 oncologic patients included cervical, endometrial,
ovarian, and other cancers (Table 2). The indications for
85 patients in group B included symptomatic fibroids,
benign adnexal mass, endometriosis with chronic pain
and endometrial hyperplasia (Table 3). Attending gyne-
cologic oncologists who were assisted by fellows and
residents in training performed all procedures. Our surgi-
cal techniques for various types of laparoscopic hysterec-
tomies have previously been described.2 After obtaining
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and
Reproductive Science, Mount Sinai School of Medicine, The Mount Sinai Medical
Center, New York, New York, USA (all authors).
Presented at the 14
th International Congress and Endo Expo 2005, SLS Annual
Meeting, San Diego, California, USA, September 14–17, 2005.
Address reprint requests to: Farr Nezhat, MD, The Mount Sinai Medical Center,
Division of Gynecologic Oncology, 1176 Fifth Ave, Box 1173, New York, NY 10029,
USA. Fax: 212 241 9434, E-mail: farr.nezhat@mssm.edu
© 2006 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2006)10:439–442 439
SCIENTIFIC PAPERInstitutional Review Board (IRB) approval, patient infor-
mation including age, body mass index (BMI), preopera-
tive diagnosis, type of procedure, estimated blood loss,
pathologic findings, and perioperative complications (Ta-
ble 4) were obtained from hospital and clinic charts.
Perioperative complications included those that occurred
during surgery or within 30 days of hospital discharge.
The data were analyzed with SPSS 10.1 (SPSS Inc, Chi-
cago, IL) using the t test for comparison of surgical data
between 2 groups. P0.05 was defined as significant.
RESULTS
Seventy-four patients underwent laparoscopic hysterec-
tomy for gynecologic cancers (group A). The indications
included 49 endometrial, 15 cervical, 7 ovarian, and 3
other gynecologic cancers. The procedures in this group
included 46 LAVHs, 24 total laparoscopic radical hyster-
ectomies (TLRH), 2 TLH, and 2 laparoscopic supracervical
hysterectomies (LSH). The additional indicated proce-
dures in this group included salpingo-oophorectomy, pel-
vic and para-aortic lymphadenectomy, omentectomy, cys-
toscopy, and sigmoidoscopy.
In group B, 85 patients underwent laparoscopic hysterec-
tomy for benign conditions. The indications included 33
adnexal masses, 18 symptomatic uterine myomas, 10
cases of persistent pelvic endometriosis, and 24 other
benign gynecologic conditions. The procedures in this
group included 59 LAVHs, 15 TLHs, and 11 LSHs (Table
3). The additional indicated procedures in this group
included salpingo-oophorectomy, colpopexy, ure-
thropexy, and cystoscopy.
Patients in group A were significantly older than those in
group B (mean ages of 57 years and 51.2 years, respec-
tively, P0.001). The mean body mass indexes (BMI)
were 27.76.7 kg/m
2 in group A and 24.33.9 kg/m
2 in
group B (P0.001) (Table 1). There were no significant
differences in the mean blood loss (group A, 201.1 mL;
group B, 183.6 mL, P0.504), conversion to laparotomy (2
in each group), and wound infection (none in either
group) in the 2 groups. The mean operating time (188.2
and 253.2 min, P0.001) and the mean length of hospital
stay (2.5 days and 3.5 days, P0.001) were significantly
shorter in the benign group. There was one bladder injury
during a TLRH in a patient with cervical cancer (group A),
which was repaired laparoscopically. Two patients in
group A and 4 patients in group B required intraoperative
transfusions. Postoperative fever defined as elevated body
temperature (38°C) on 2 occasions occurred in 4 pa-
tients in group A and 2 patients in group B (Table 4).
Table 2.
Indications for Hysterectomy in Group A
Indication N LAVH* TLRH* TLH* LSH*
Endometrial cancer 49 40 9 0 0
Cervical cancer 15 1 13 1 0
Ovarian cancer 7 5 0 0 2
Vaginal cancer 1 0 1 0 0
Peritoneal mesothelioma 1 0 0 1 0
Uterine papillary serous CA 1 0 1 0 0
Total 74 46 24 2 2
*LAVH  laparoscopically assisted vaginal hysterectomy; TLRH  total laparoscopic radical hysterectomy; TLH  total laparoscopic




(n  74)* M
(SD)
Group B
(n  85)* M
(SD)
P Value†




27.7 (6.7) 24.3 (3.9) 0.001
Gravidity 3 (1.5) 3.5 (1.6) NS
Parity 1.7 (1.3) 2.5 (0.5) 0.001
*Group A  laparoscopic hysterectomy for gynecologic cancers;
Group B  laparoscopic hysterectomy for gynecologic benign
conditions; M (SD)  mean (standard deviation).
†t test.
Comparison of Laparoscopic Hysterectomy Morbidity for Gynecologic Oncologic and Benign Gynecologic Conditions, Mahdavi A et al.
JSLS (2006)10:439–442 440DISCUSSION
Since the introduction of explorative laparoscopy, opera-
tive laparoscopic techniques have been applied to a vari-
ety of benign adnexal and uterine conditions.3 These
successes have prompted the development of laparo-
scopic techniques for the exploration, staging, and resec-
tion of pelvic malignancies. Techniques range from full
laparoscopic procedures to laparoscopic-assisted proce-
dures in which a portion of the procedure is performed
vaginally.
Laparoscopic hysterectomy has been utilized in the man-
agement of gynecologic cancers including endometrial,
cervical, early ovarian, fallopian tube, and vaginal cancers.
Laparoscopy has been reported to provide the exact stag-
ing and treatment of patients with endometrial cancer
with a shorter hospitalization, and earlier recovery, and
improved quality of life.4 Nonetheless, the number of
patients included in such a series has been low, and
additional data are required concerning long-term survival
in patients treated using the laparoscopic approach. A
randomized clinical trial to compare the effectiveness of
laparoscopic surgery with standard surgery in treating
patients with endometrial cancer is being conducted by
the Gynecologic Oncology Group (GOG-LAP2). Mean-
while, no evidence supports prohibiting laparoscopic sur-
gery in patients with endometrial cancer.
Until recently, laparoscopic radical hysterectomy had
not been widely accepted in the United States. The first
case of a laparoscopic radical hysterectomy and
paraaortic and pelvic lymphadenectomy to treat a stage
IA2 carcinoma of the cervix was reported by Nezhat et
al5 in 1992. Subsequently, several reports from author-
ities worldwide6,7 have described various methods and
techniques to streamline the operation while achieving
the maximum efficacy in terms of oncologic outcome
and minimization of perioperative complications. To
date, no randomized trials have compared laparoscopic
versus open radical hysterectomy; such a randomized
trial for malignancies would require an unattainable
number of patients.8 However, many nonrandomized
reports suggest that the advantages of laparoscopy in
oncology are similar to those proven for benign dis-
eases, including faster recovery, fewer complications,
and less blood loss.9–11
Table 3.
Indications for Hysterectomy in Group B
Indication N LAVH TLH LSH
Symptomatic fibroids and/or fibroid uterus 18 12 0 6
Adnexal mass 33 23 7 3
Endometriosis and pelvic pain 10 4 4 2
Genital prolapse 4 3 1 0
Endometrial hyperplasia 6 6 0 0
Cervical dysplasia 10 7 3 0
Family history of breast/ovarian cancer 2 2 0 0
Breast cancer 1–2 gene mutations 2 2 0 0
Total 85 59 15 11
*LAVH  laparoscopically-assisted vaginal hysterectomy; TLH  total laparoscopic hysterectomy; LSH  laparoscopic supracervical
hysterectomy.
Table 4.







Duration of surgery (min) 253.2 188.2 0.001
Hospital stay (days) 3.5 2.5 0.001
Estimated blood loss (mL) 201.1 183.6 0.504
Transfusion (n) 2 4 —
Laparotomy conversion (n) 2 2 —
Intraoperative Bowel injuries (n) 0 0 —
Intraoperative Bladder injuries (n) 1 0 —
Postoperative fever 38°C (n) 4 2 —
*Group A  laparoscopic hysterectomy for gynecologic cancers;
Group B  laparoscopic hysterectomy for gynecologic benign
conditions.
†t test.
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laparoscopic hysterectomy is comparable in patients
with benign and oncologic gynecologic conditions. In
our series, the same operators in both groups per-
formed the procedures, and the same perioperative
care protocols were followed. In spite of the older age
and longer procedures in the cancer group, the mean
blood loss, conversion to laparotomy, and wound in-
fection rates were similar in the 2 groups. As expected,
the mean operative time and the mean length of hos-
pital stay were longer in the cancer group without
affecting the postoperative complication rate. To the
best of our knowledge, this is the first report comparing
laparoscopic surgery morbidity in benign and gyneco-
logic oncologic patients in a single institution. We believe
this study is consistent with previous retrospective studies
showing the feasibility and safety of laparoscopic hyster-
ectomy for gynecologic oncologic indications.
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